nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01752257,EF5 in Melanoma Patients,0.002210210101481055,0.001004560648989096
NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",0.0007256802297231509,0.0009675621543600301
NCT01748747,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,0.001050953419840024,0.0013247839396066836
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,0.0010268849374906281,0.0007286968950205168
NCT01703507,Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma,0.0008987242949303474,0.0009616541157504332
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,0.002210210101481063,0.0024209356181150096
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.0009665628007529965,0.0007654842376875876
NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer",0.0010594013837465967,0.0012370671657208356
NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,0.001062434239340254,0.001123061802406699
NCT01744171,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,0.0012959842992821841,0.00146547671668365
NCT01744860,Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples,0.000772301894165902,0.0009582704395934303
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,0.0009555917884484181,0.0009679403720194045
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002),0.0010262737730251967,0.0008855729961470839
NCT01776905,In Vivo Real-time Detection of Circulating Melanoma Cells,0.0010595409826060556,0.0007549022336988184
NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,0.0010951004350502683,0.0010781746851085518
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,0.0011272495699469307,0.001008159607969607
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",0.001161074686744074,0.001141982322046755
NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,0.0011362543739003772,0.001303150208392352
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,0.0009170039099369273,0.0009844133388213494
NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,0.0011580732343248966,0.0011759556251273626
NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),0.001220507090374844,0.00121373663112204
NCT01721603,A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,0.0008715459203293369,0.0009171871876240653
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001130860976441792,0.001227990150498983
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,0.0014941033533008043,0.0009024776754823175
NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,0.0010508636902302766,0.0010521448345788235
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,0.0009270140070850146,0.001045594798072101
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0008583881691920017,0.0008803814876345407
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,0.0008857480672687782,0.0009991215887050183
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,0.001131289151135597,0.0009293472807777052
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,0.0014368188355306378,0.0011688256853299957
NCT01709162,Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma,0.0009851884355087377,0.0011911067601584142
NCT01782508,A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma,0.0009017181272556716,0.0008957330533692798
NCT02836548,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,0.0008461999003108046,0.0010544311718348948
NCT02891616,18F-FLT PET Imaging in Patients With Advanced Melanoma,0.0011800500888755443,0.0011774461271943431
NCT02879474,Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma,0.001021365324753231,0.0008399545393184006
NCT02819843,"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",0.0008778490557074238,0.0009038634722759685
NCT02884362,Prospective Melanoma Database,0.0014537688988707214,0.0005294658295162845
NCT02883933,Clinical and Histological Features of Head and Neck Melanoma,0.001039808519375717,0.0005820025072374705
NCT02828202,Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients,0.0013018750543718866,0.0014569611892455315
NCT02828345,Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma,0.001233589581782378,0.0012143923209925753
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,0.0007797397770307131,0.0009686525826526276
NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",0.0008301568852619156,0.0010342641127466879
NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,0.0010663753179719448,0.0008861066764365567
NCT02854657,Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners,0.0010719457101078707,0.0009429361533904961
NCT02897765,"A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",0.0010133843493055803,0.0011709017590897694
NCT02818023,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,0.001036513608224225,0.0013159486100166623
NCT02838433,Study of Anti-telomerase T CD4 Immunity in Melanoma,0.0012594753515739897,0.0010269946317862403
NCT02870244,Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes,0.0008863899829269464,0.0007625834755565057
NCT02862145,"Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions",0.0011377038544962473,0.0009747443047975892
NCT02862743,Molecular Characterization of Advanced Stage Melanoma by Blood Sampling,0.0008235947706579236,0.0008428461983108797
NCT02823405,X4P-001 and Pembrolizumab in Patients With Advanced Melanoma,0.0013675208361898,0.001102212580228639
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,0.0010080467231022856,0.0010983119972972017
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,0.0015330000621296771,0.0012860501700567802
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,0.0008506753908055182,0.0007566424301642204
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,0.0014215663872517966,0.0014443444820665297
NCT01528774,Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers,0.0007592458576035836,0.0008856109723905008
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,0.0012202059807887701,0.0010751371326823977
NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,0.0011256230139642927,0.0013456266205145583
NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,0.0012281900734299354,0.0010712395990302827
NCT01551693,STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma,0.0013018750543718866,0.0010345679496073336
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,0.0012944536416108997,0.0010205836988261263
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",0.0009175303910186244,0.0009936460295461034
NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,0.0008672295141256284,0.0011700467956048597
NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,0.001080186175017949,0.0010523237209605007
NCT01502293,Trial of pIL-12 Electroporation Malignant Melanoma,0.001032810660651408,0.0010440573619539377
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,0.0010258846487393297,0.001057723414444944
NCT01558349,Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques,0.001456764130830844,0.0010935715591250481
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",0.0012431460206309042,0.0015180620891071409
NCT01531608,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma,0.0008557146231378058,0.0008667041162202168
NCT01531244,"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",0.0008201169320910324,0.001159781274925743
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,0.0008460912483364508,0.0010658460728808377
NCT01500304,Minimally Invasive Groin Dissection for Melanoma,0.0008319115926924585,0.000894696012190649
NCT01563614,"A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",0.001011593586546426,0.0008291425152789233
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,0.0012436795123024682,0.0010950743439434166
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery,0.0010909786578793387,0.0013959446124568876
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,0.0009219322134586288,0.0009484871671709128
NCT01556503,Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis,0.0008479889361749504,0.0008744667491529084
NCT01503827,Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma,0.0007733156535685352,0.0007251304196297862
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,0.0012197807118758017,0.0007964145073003965
NCT01543113,"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project",0.0007835850911657927,0.0010842954312795694
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,0.0011298411724826754,0.0013625812788383704
NCT02203864,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,0.001183421406418983,0.001216349305424914
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,0.000906099393763571,0.0009719905056352234
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",0.0010634790740925817,0.0011597746601733734
NCT02251314,Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma,0.0010713838586037072,0.0008452526261524157
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,0.0012192156628111205,0.0014441965213698156
NCT02225366,Intratumoral Injections of LL37 for Melanoma,0.0014639946636531749,0.0010969635996446307
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,0.001105657327243906,0.001147974526178619
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,0.0012191718785756198,0.0009981687329516608
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,0.0008731624298497749,0.0009864664212366327
NCT02211131,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,0.0009058351996178563,0.0010563560851974223
NCT02297529,Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma,0.0009834125111607952,0.001152241773845241
NCT02236546,FDG-PET in Advanced Melanoma,0.0011932469479189105,0.001068961980608032
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,0.0013611219942335302,0.0013003282193790092
NCT02263508,Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034),0.0008750556195677642,0.0008155918759798928
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,0.0015843147166427786,0.0011415298748996482
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,0.0008748037780366874,0.0011191100052109838
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,0.001114852372182523,0.0012556414083948904
NCT02231775,Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo),0.0010546627617361887,0.0011050968561296017
NCT00590824,Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma,0.0010725037121114723,0.000827133855585103
NCT00591500,A Model for Genetic Susceptibility: Melanoma,0.0008342191013316358,0.0007292684543497638
NCT00591370,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,0.0012399944040737698,0.001084158121681114
NCT00518206,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,0.0013061668579213502,0.0011736421773588385
NCT00518895,Trial of Dacarbazine With or Without Genasense in Advanced Melanoma,0.0009751776702773723,0.0009150690505908359
NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,0.0009066950736670433,0.0009269860927666286
NCT00580060,"Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",0.0009922070776743836,0.001139107874585103
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,0.0009692914007830444,0.0011325727282797107
NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,0.0012678792449773925,0.0009619326051508208
NCT00510302,Melanoma Risk-Reduction Among Patients and Family Members,0.0012186855373282888,0.0007070595564177368
NCT00584493,Treatment Use Study for Advanced Melanoma.,0.0012001368680674912,0.0014695348143371608
NCT00581698,Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue,0.000699193943264775,0.0008422895280378067
NCT00526032,Melanoma Detection by Oblique-Incidence Optical Spectroscopy,0.001030897547904794,0.0006017953590364502
NCT00565968,Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg,0.0010315069800090335,0.001018237707711677
NCT00596362,Treatment With Intravitreal Avastin for Large Uveal Melanomas,0.0011120624611481629,0.0011073404961243066
NCT00533702,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,0.0010771658257736556,0.0010688284059972941
NCT00553618,"Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients",0.0010173263102897744,0.0011332310966265682
NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,0.0010730522555462976,0.0011385050296077069
NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,0.0011740632479045063,0.0010390058823826422
NCT00525031,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,0.0010209705871910089,0.001385893404495503
NCT00522834,Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma,0.0008500504026423237,0.0007667190539664286
NCT00521001,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,0.0011183292151015667,0.001105652062191844
NCT00585000,"A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",0.0012243741944239451,0.0013023551671551032
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,0.0010949591414084524,0.0012189007262208694
NCT00588198,"Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma",0.0009707735823200276,0.001240724609104724
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,0.0010677600187833096,0.0012000323015938787
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,0.0012258068113262656,0.001301783349104057
NCT00506311,Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients,0.0012275972143157507,0.0006942037785008244
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,0.0010329643303914086,0.0010057574041588957
NCT00568451,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,0.0011107721182279048,0.0010997369784292157
NCT00568048,Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011236455674934855,0.0010879421712747448
NCT00507325,Sample Collection From Melanoma Patients,0.0015320300694230797,0.0012005449373474538
NCT00536029,MicroRNA Expression and Function in Cutaneous Malignant Melanoma,0.0010290025451569012,0.0006729547340920271
NCT00512798,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,0.0011295480999857486,0.0010536329585168604
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,0.0014552309516847987,0.0009115872528317518
NCT00527761,Taxotere/Temodar/Cisplatin Study in Melanoma Patients,0.0011308427167551643,0.0011068829685645521
NCT00527657,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010856670686025679,0.0010542585542866472
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,0.001214095353762565,0.0008922026289731002
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",0.0010379093463007347,0.0010355221345610215
NCT02739386,Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases,0.0011601832108874503,0.0009793129006722995
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,0.00112353124357229,0.0011073834497537223
NCT02791594,Imaging FDG Flare in Melanoma,0.0010363781248325904,0.0010050255776722183
NCT02723721,Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face,0.0008350410673069816,0.0008387063922883386
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",0.0009301959627268366,0.0010500611456368237
NCT02717364,"Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma",0.0011057138160696246,0.0009483247629885502
NCT02799901,Nivolumab Plus Radiotherapy in Advanced Melanoma,0.000996518336098622,0.0008258579097921299
NCT02794636,Interferon Toxicities in Melanoma Treatment,0.0009063268349229197,0.0010521852420372084
NCT02716948,SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,0.0009909761252776333,0.001210601219867646
NCT02716077,Early FDG PET in Melanoma,0.0014537688988707214,0.0007960480373742696
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0011819658660830099,0.0013362255684642534
NCT02744209,Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients,0.0011256579422845568,0.0012611685931740169
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,0.0008971893674925795,0.0011668496676074003
NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,0.001073661355176175,0.0009729536963427499
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",0.0009120905647819098,0.0013462574127259728
NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,0.0009079377751171875,0.0009065010483857714
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,0.001263784326590623,0.0011984437523960586
NCT02759536,In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma,0.0011139811022447903,0.000913201407243178
NCT02700763,[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis,0.0010486548695093666,0.0009713096114376003
NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,0.0010129927459439285,0.0012020462661123164
NCT03028948,Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma,0.0009865753701782175,0.000953359554577559
NCT03084640,Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,0.0009839710801045,0.0009139991399848862
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,0.0008721821773434275,0.0009450299321550175
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,0.0007367470497443968,0.0007985365365572631
NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,0.0009736650223645604,0.0014078681177713142
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,0.001131145985017844,0.0012593902956700455
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,0.0010135947401196225,0.0010095309393166635
NCT03007823,High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma,0.0007846465461855476,0.0011990657377284844
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,0.001191278132917631,0.0010481277504167167
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",0.001051148432525915,0.0011022754043257578
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011077683735886972,0.0013146851072871999
NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,0.0010013823905528,0.0010442435166657718
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",0.0012214105489895708,0.0010150421384509801
NCT03086174,Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma,0.0010307926475179642,0.0012133880396178367
NCT03012009,Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial,0.0007275660532139023,0.0006906224609458412
NCT03073031,The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy,0.0015540773378102338,0.000936649055971444
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",0.0008378959344163723,0.0004993733607436211
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),0.0010974795724143093,0.001168228849290749
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,0.001213993125211686,0.0013860087733395035
NCT03033485,18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis,0.0007550865895525202,0.0010056447790378108
NCT00203008,A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma,0.0011322540370315012,0.0011836326431711658
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,0.0007892373073119991,0.0008413713895170471
NCT00255762,"Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",0.0010995125472849274,0.0010807760297709208
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,0.001031070743451812,0.001164959349841277
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,0.0010188895416545665,0.0009575795485050396
NCT00243061,AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma,0.0017010256318265712,0.0013505238116823706
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,0.0010357055108522217,0.0010555478336850101
NCT00204529,Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB,0.0012609272769047175,0.0012084607081051905
NCT00204581,Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases,0.0007708835943329157,0.0009353009163026815
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma,0.0010327678334788864,0.001296338134890221
NCT00278122,Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.001184581093487555,0.0012915843578935467
NCT00264056,Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases,0.0010736829073424367,0.001174726673659784
NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,0.0010848296139636358,0.0010417986968275857
NCT00281541,A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma,0.0010878902157696044,0.0014512213599164154
NCT00288938,Natural History Study of Moles and Suspicious Melanoma,0.000889647042539298,0.0009136291071660637
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma",0.0007964467155609629,0.0012570709810132948
NCT00246012,"A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma",0.0009442439952612689,0.0011446882277028224
NCT00273910,Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma,0.0007833672248631984,0.001410890028547462
NCT00217542,Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery,0.0011603803178829718,0.0011570683634911714
NCT00232726,Clinical Study of Previously Untreated Patients With Malignant Melanoma,0.0012272534143880796,0.001169294069840494
NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,0.0007808543446451358,0.0009646479146254406
NCT00289640,Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012913800846602087,0.0014784103422230443
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,0.0011726519147807319,0.001352140749410812
NCT00289627,A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012268006002366665,0.0012208841040019743
NCT00226473,Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma,0.0007498328540196441,0.0010177298603659503
NCT00258687,"Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma",0.0008051104753559351,0.0010285079500617065
NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",0.0011784813089464,0.001248016561284028
NCT00272415,"A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",0.001120276680591174,0.0010265859118385257
NCT00287196,Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes,0.0007518772462077203,0.0006681407122832971
NCT02366195,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,0.0007111575971433588,0.00099213328340401
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,0.0008628025695406278,0.0008771001606308559
NCT02352623,Quality of Life and Surgical Late Effects of Melanoma Treatment,0.0009546624328065622,0.0011085173975550683
NCT02335476,Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography,0.0008378915307089385,0.0006692584077137267
NCT02332668,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",0.000927212085645313,0.0009952382025540912
NCT02310451,Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes,0.0008933417235949016,0.0011037296993959287
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,0.0014537688988707214,0.0009661467566342036
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,0.0009345328249928402,0.0011551313055898408
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),0.0009207564821019323,0.0008961889317246494
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,0.0012292452198911271,0.0011663864088827438
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.000835565502710869,0.000839498781162906
NCT02375984,A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas,0.0008810263932015431,0.0010140185590185096
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),0.0009638110363691232,0.0010342549405630128
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,0.0011338042874851815,0.00123847547966307
NCT02385214,MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma,0.001027832025953692,0.000691350029924721
NCT02385253,Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance,0.0006991383830310124,0.0004780310249471951
NCT02374242,Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases,0.0012440811949450236,0.0012726343816694557
NCT02320058,A Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab by Itself,0.0011654215546958032,0.0011187472814367515
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,0.001018655655925648,0.0011718989180153655
NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,0.0008662079322209932,0.0007120837232085301
NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,0.0011038411823539591,0.0013137001036576557
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",0.0010069648164756655,0.0011611466913633251
NCT02302339,A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma,0.00120957434894788,0.0012653322650020764
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC,0.0008721821773434275,0.0009343803475071398
NCT02331134,Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,0.0006999311722628011,0.0008378054061559192
NCT02355574,5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results,0.0008031575833177412,0.0006543124040560049
NCT02355587,Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes,0.001132413506452622,0.0008529116752224379
NCT02307149,Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,0.0013722598711513926,0.00149534343507385
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,0.002786251250086908,0.0009230890705330925
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.00084159058553312,0.0007999525986958359
NCT02393001,Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques,0.000703244869888065,0.0008040835904482549
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011334358157392402,0.0012641288728824115
NCT02339987,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,0.0008694900731146633,0.0012477717332616324
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,0.0010951006985822438,0.0012158791779138583
NCT01308762,"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients",0.001119324977870716,0.001371945621839711
NCT01388569,Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim,0.0011054852936139444,0.0011904707380854043
NCT01336270,"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients",0.001094021198011576,0.0010737600462494815
NCT01341158,NAM-Trial: Multiferon in Malignant Melanoma,0.0014537688988707214,0.0008340552409748838
NCT01328535,Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011642395385827317,0.0013107859693528153
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,0.0011133009007249018,0.0012889092500474454
NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,0.0012307664933660538,0.0012262512242364437
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,0.001168809781668891,0.001409736534416687
NCT01311466,Liver Transplantation and Uveal Malignant Melanoma,0.0014537688988707214,0.001033643411158572
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,0.0008834791394965424,0.0010427252141959142
NCT01356771,Melanoma Risk Assessment & Tailored Intervention,0.001025860602268332,0.0006699740969003207
NCT01302496,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.001174013394355204,0.0010422863620959206
NCT01355120,THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease,0.0013447483484860063,0.0011086430801568595
NCT01355562,Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer,0.0007486900771097375,0.0009636652392649922
NCT01359956,Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma,0.0008596657814333889,0.001033299188776926
NCT01397708,Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma,0.0009278860507362621,0.001038615286765561
NCT01338389,Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy,0.0010018380684596118,0.0010389595070193585
NCT01316692,Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma,0.0011955126117834845,0.0011493285615128703
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,0.0012584754993603333,0.0012950281562775783
NCT01363206,Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma,0.0008040830307850362,0.0009451927991037759
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",0.0010376519481969998,0.0013648338599799746
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,0.0011823797171183084,0.0011752665995432717
NCT00813449,Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma,0.0011941011795732286,0.001037439729951053
NCT00871533,Pilot Study of IFN α2b for Melanoma Patients,0.0017627199232994701,0.0010896035581736145
NCT00811759,Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma,0.0011873913687538021,0.0011630165838455758
NCT00816374,Tailored Intervention for Melanoma Patient's Families,0.001531047653790355,0.0008301247287031331
NCT00831545,"Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",0.0008566493658294958,0.000982290924227845
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,0.0012607497758118052,0.0012865999539774632
NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.001179065702617808,0.0013145323395861166
NCT00862914,"Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi",0.0006958836395635147,0.0006368148765551711
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.0010795534629153645,0.0010493335609619663
NCT00835419,Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression,0.0009002098291051985,0.0014015210194129948
NCT00835133,"Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma",0.00096331117764456,0.0009527966989866535
NCT00861406,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,0.000838509237860498,0.0008802899744796257
NCT00849407,Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma,0.0007399172826100163,0.000721068424102472
NCT00889980,Melanoma Molecular Profiling Analysis,0.0014582871483508181,0.0007627183210185824
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,0.0010763345469130732,0.0013301426807899015
NCT00847522,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma,0.0010182262729704018,0.0010185027436601713
NCT00897520,Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy,0.0010913841291485206,0.0011745308862569387
NCT00897481,Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy,0.0011034581749970736,0.0011153943951677336
NCT00897546,Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma,0.0010842359762620606,0.0011495178007264726
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,0.0010676332745142853,0.0010845315448674289
NCT00809588,"Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)",0.0007035698396711557,0.0009153631447853878
NCT00841204,Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma,0.0010258888541206208,0.0008230006587327708
NCT00839410,Multicentric Cohort of Melanoma Patients in Ile de France Area,0.0015300581169501728,0.0009048353904844025
NCT00803374,Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma,0.0013223673057522235,0.0016738601156449408
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,0.0011227410897398519,0.0011782659420853758
NCT00846833,Haploidentical NK Cell Infusion in Malignant Melanoma,0.0008588705431348487,0.0009543979170789806
NCT01644591,Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases,0.0010063688529606974,0.0010544683673058895
NCT01673854,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,0.0010676389361498277,0.0015034960848668453
NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,0.0012634945346616001,0.0009700136635580602
NCT01676649,Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma,0.0011867250516165882,0.0010810800087366302
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,0.0009749315917911355,0.0010202924300911586
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,0.000998807933539498,0.0012518995182251224
NCT01636882,Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks,0.0015751498773297935,0.0012999706308199207
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),0.0012751961663891261,0.001148565105309076
NCT01666418,Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel,0.0011697457067826951,0.0013263032960519076
NCT01610531,COPARIME: Pilot Study of a Target Detection of Malignant Melanoma,0.0012635179505697308,0.000847145515648003
NCT01622933,Multiple Antigen-Engineered DC Vaccine for Melanoma,0.0014906427323786626,0.0006648932955018421
NCT01681212,Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma,0.0012844064265980484,0.0013515390211128618
NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",0.0010941909769169775,0.0011693037089235332
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,0.0010758216293064316,0.0014707385093832724
NCT01682083,A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,0.0009433285720954341,0.001031975688225403
NCT01672450,A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma,0.0011839163557041314,0.0010279497966515286
NCT01677975,"The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma",0.0009612810064198859,0.0011008529802599772
NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,0.0014537688988707214,0.0012170607504107846
NCT01662713,Optical Frequency Domain Imaging for Non-melanoma Skin Cancers,0.0008453500745832462,0.0008004245990269144
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,0.0009075366952238369,0.001121262220932408
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,0.0012433571627542554,0.0011699184535755693
NCT01667419,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,0.0011591556945346278,0.0008935213733978922
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,0.0010254650658607174,0.0011142530597135463
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",0.0009885760856259596,0.001028237446053856
NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,0.0013393534370551652,0.0011596498464785316
NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,0.0009040689949345411,0.0009409681314507401
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,0.0012825595384260333,0.0011450183457336724
NCT01082198,Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes,0.0010954654609357584,0.0011118331121501772
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,0.0009669025512971959,0.00102299515706628
NCT01039844,Study of Weekly LOC-paclitaxel Injection for Melanoma,0.001016720688549989,0.001055862007305825
NCT01003626,Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients,0.0012133712641480374,0.00124338826157714
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",0.001027359435002452,0.001039665889694674
NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,0.0013304969131101838,0.001237001642455891
NCT01067066,A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma,0.001072869252386983,0.0010604028791605436
NCT01085396,Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin,0.0006824854409239898,0.0007095736613705587
NCT01034696,Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting,0.0009847531100424115,0.0010687763557551116
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,0.0009848138032394948,0.0014294122021047545
NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,0.0007492460187422967,0.0011110607064660325
NCT01021059,A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer,0.0008766233315036615,0.001470787115411921
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0010775778028719143,0.0011266421228762825
NCT01002560,The Identification of Novel Prognostic Markers in Melanoma,0.0008486979441465934,0.0010192974776888693
NCT01077050,SciBase International Melanoma Pivotal Study,0.0018006310967869853,0.0007869233910337025
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.001181251165372103,0.001131792061633451
NCT01092585,Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH,0.0010966631600313804,0.0010796766066453146
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",0.0010059281165971142,0.0011949765429431194
NCT01011530,Dose Escalation Study of MLN4924 in Adults With Melanoma,0.0018006310967869853,0.0011664767867750037
NCT01009775,A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma,0.0010480930473891412,0.001209149974933523
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,0.0014155371109318361,0.001114366585062061
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.001182608730815185,0.001254751319539471
NCT02425475,FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA),0.0010308893345641575,0.000499604093682077
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,0.0009814995363501596,0.001032344983232969
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,0.0009797924071588777,0.0010274647951290107
NCT02442466,Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma,0.0008932272363937308,0.0008186424185365244
NCT02457065,Skin Care Behaviors Among Melanoma Survivors and Their Families,0.0010259011646768306,0.0007484636503851747
NCT02410733,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,0.0010717475165601825,0.0013650649809408841
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,0.0008478652167567115,0.0010857236981334816
NCT02437279,Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients,0.0011746425872059762,0.0013201283930186721
NCT02437305,Melanoma Perception and Health Literacy in People of Color,0.0008311268826501695,0.0006786696149453951
NCT02437136,Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,0.000911905185044109,0.0009613967758700375
NCT02492815,"PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma",0.0011337558105964172,0.0012717895400334968
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,0.0009712798889805799,0.0012011863249151672
NCT02452294,Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER),0.0010775713347253473,0.0010415655250012757
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,0.0012522020187803265,0.0014005351855328715
NCT02470273,Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID),0.0010033580281988645,0.0007829169163908349
NCT02402699,Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan,0.0010936965878860336,0.0007780651939233231
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,0.0011944528254433306,0.0009103893363653954
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,0.0009585857031543321,0.000983939528698762
NCT02434107,"Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)",0.0009702317740320494,0.0008344183904743495
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,0.001240752858100968,0.0012140993611300488
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma,0.0009162169041365583,0.001338068402173574
NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,0.000976250778956985,0.0010335002665900744
NCT02451488,Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma,0.0007402124003229309,0.00070925554958239
NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,0.0008056622441027021,0.0009440877942234718
NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,0.0011102997085125767,0.0010599936257027853
NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,0.0006972510510372198,0.0009098941836756207
NCT00104845,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012238164513765984,0.0012795719301549595
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0013018750543718866,0.0012652656479191949
NCT00104988,S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011203338081196307,0.0011378049512157581
NCT00104897,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma,0.001266392864404196,0.0011405994868182497
NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,0.0011444607320964658,0.0012063497070324844
NCT00184067,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,0.0010160459661353628,0.0010755500016100853
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,0.0011410248711904842,0.0010492842928303684
NCT00110019,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011576169739731961,0.001339525140260599
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010327673749134837,0.001069854103477403
NCT00119249,Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011840248920749225,0.0011834270141467913
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),0.0007606769662663321,0.0010399061503883313
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,0.0012007347439176863,0.0013547025908726509
NCT00109863,Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma,0.0013463133253372311,0.0013434948499002955
NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,0.0009779924347620738,0.0008929922989071211
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,0.001229737737306423,0.0012471426415454664
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,0.0011900272367881633,0.0014370363365114292
NCT00128583,Vaccine Therapy in Treating Patients With Malignant Melanoma,0.0015849858625954353,0.00127228274610263
NCT00199901,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma",0.001152241642469522,0.0012451284596786281
NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",0.0012311057660403394,0.0009597484016048527
NCT00118313,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011753078160798476,0.001294676492661992
NCT00118274,"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011762769156334952,0.0013316176497069087
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0008515414259686152,0.0010561269537234209
NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,0.0013491058066239325,0.0010526433252975838
NCT00112216,Immunotherapy of Melanoma Patients,0.0015540773378102338,0.001105686692207379
NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,0.001180889257079817,0.0013801279307252454
NCT00153569,Multiepitope Peptide Vaccination in Melanoma,0.001062434239340254,0.0008410869266375984
NCT00116363,Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma,0.0012151402979899426,0.0015958031244131666
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,0.0012087212304700773,0.0012446641987872654
NCT00108875,"Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer",0.001059182410719497,0.0012119550344970994
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,0.0010908248816713917,0.0010460824809905458
NCT00126685,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013875747156188902,0.001202575830271582
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,0.0011384354698086847,0.0011285489688369545
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",0.0011562560111817743,0.001102326268036274
NCT02180061,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),0.001160447114369571,0.0013189228796568946
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),0.000972635976006743,0.0009810718535227321
NCT02177110,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma,0.0008579474818286012,0.0010058731846653496
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon,0.0010212454631853894,0.0011072609243242238
NCT02166255,"APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",0.0010552355413334486,0.0011918874322084199
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",0.0010004695111617405,0.0010731818379708438
NCT02147951,"Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",0.0008796110849107553,0.0013516863377695287
NCT02193581,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0007025041371954798,0.0006989430187281855
NCT02106598,"Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Gynecologic Malignancies",0.0006855711630199872,0.0009562400120342232
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,0.001125696688711488,0.0012603085666984338
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,0.0010413993975794138,0.0013267140388605856
NCT02190838,Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma,0.0007214662669134152,0.0008456253132612337
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,0.0013107369193218156,0.0012492822670185813
NCT02158520,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011263232910429166,0.0013468516384102808
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",0.0008867928142116142,0.0010379858547507623
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,0.0011134519608838659,0.0012706697359248433
NCT02155322,A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400),0.0010829092445737458,0.001763619590006821
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,0.0010356467870490577,0.0011524155599208525
NCT02115139,GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases,0.0011553199670258768,0.001180118905554842
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma,0.0010565321235901613,0.0011317890764662203
NCT02142335,Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma,0.0011216786890243164,0.0012978597637039377
NCT02142244,Fluorescence Surgery for Sentinel Node Identification in Melanoma,0.0008931260830670044,0.0007381874222879477
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,0.0009995741511343893,0.001177833346316793
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,0.001160400161423569,0.0010814139753447737
NCT01174238,A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852),0.0008399965272195179,0.000950489734613205
NCT01120275,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,0.0013456770702472496,0.0011642139869129176
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,0.0008417305377443127,0.000603784535477924
NCT01127594,Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion,0.0009907571798879332,0.0012346363552235824
NCT01127451,Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma,0.001248250914830184,0.0013252452623162565
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",0.0011770330891598335,0.0013039695785111325
NCT01183936,Trial of Surgical Excision Margins in Thick Primary Melanoma,0.001100950023852448,0.0009728815253431745
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,0.0012815102469172783,0.0011293246251554956
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,0.0010773504406648125,0.0008693469444002328
NCT01191294,Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma,0.0007145930047208173,0.0005062207838088257
NCT01121718,NIR-Guided Sentinel Lymph Node Mapping in Melanoma,0.0010279948584724756,0.0007735472799725809
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,0.0008823974300413244,0.001132226906005033
NCT01134614,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.001205809669008663,0.001152544179353253
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",0.0014010724101622702,0.001313434773859188
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,0.0009965237732632588,0.0010022844725877753
NCT01118832,Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi,0.0007198788583311472,0.000586111552008647
NCT01168050,Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.,0.0008716345240074689,0.0008909587770511603
NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,0.001048841144656082,0.0010326195430292813
NCT01136967,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",0.0010104973550125623,0.001130438480477105
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),0.0008405569253677206,0.0009566494445176586
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,0.002786251250086908,0.0013023932144876815
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,0.0008951767916122015,0.0009128095914628133
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,0.0013722598711513926,0.0009831364319958422
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,0.0013365339353272408,0.0012026926196782484
NCT02009384,Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox,0.0008779647368708665,0.0009721363808193281
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,0.001260564068836887,0.0012309664654005343
NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,0.0012574353682693945,0.001327051409867756
NCT02094391,"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",0.0011282392985598859,0.0009284351403657616
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,0.0012674213291280294,0.0011608009669731684
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,0.0008720653414870877,0.0011391990856379115
NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,0.0008632103584791117,0.0009853169313995228
NCT02056522,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0007025041371954798,0.0006989430187281855
NCT02074605,Cognitive Effects of Interferon in Patients With Melanoma,0.0015429491146078836,0.0009729141749706601
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,0.0012365760432317071,0.0013425639030309488
NCT02029729,RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER,0.0008701796790170751,0.0010274865865237733
NCT02058953,"CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases",0.0010390327738024892,0.0009758905718325417
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,0.0012431025227731334,0.0010557104612001493
NCT02088762,Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm),0.0012241899250168753,0.0007327884764658291
NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,0.0009176292684253404,0.001058405212695128
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,0.0010525113038345087,0.0011612666704591823
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,0.0008322492377495992,0.0009820620849266084
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers,0.0010935127099180192,0.0012550458214514832
NCT00938223,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",0.0010704293215763228,0.0010509409020449723
NCT00928902,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",0.0009960608419337738,0.0010568198625596171
NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",0.001080801211556662,0.001105980341846769
NCT00942162,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,0.0012552362068288846,0.0012327061214003536
NCT00936221,Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients,0.001015074598461435,0.0009739432854119357
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,0.001250300503488878,0.0013327054559088714
NCT00966173,International Melanoma Algorithm Training Study - IMATS,0.0010148285705367287,0.0007580614543601737
NCT00920907,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,0.0008438255308783942,0.0010655509849426118
NCT00972933,Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma,0.0008160826004767793,0.001054803506904624
NCT00901966,Sun Exposure and Melanoma in Agricultural Workers,0.001455247913920362,0.0006947922585147808
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,0.0008182076565642773,0.001186829677721994
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,0.0012194202167230426,0.0011238632325665204
NCT00923169,Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma),0.001224577223200497,0.001376132592522076
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.0011403954152549895,0.001329930389299564
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,0.0008440985644488673,0.0007619415056475599
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,0.001093826620485624,0.0011039076174892872
NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,0.0010150571887475896,0.001177434087009501
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12",0.0011688256945034123,0.0009416626959327261
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",0.0010073667117525427,0.0010108020007023612
NCT00912730,A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma,0.0008954459911372387,0.00090356756780913
NCT00912418,"Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",0.0011531539741899566,0.0010237890809059696
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,0.0009829579385206729,0.0009865705940194452
NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,0.0011566061472286801,0.0009484490442768578
NCT00961376,Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC),0.001017898079123285,0.0012245317475831382
NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,0.0009915322608393233,0.0008576428141614362
NCT00962845,Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011795843758750897,0.0010751053828437752
NCT00991250,SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma,0.0010212454631853894,0.001545502795868448
NCT00991991,"Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",0.0012040029746729955,0.0012635975987251365
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",0.0010325073344499456,0.0011751508373692293
NCT00937625,T-cell Based Immunotherapy for of Melanoma,0.0014890687869799635,0.0012033584590461649
NCT00937781,Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690,0.001165823867835587,0.0012308063853022422
NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,0.0013463953528624077,0.0012716818967475584
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,0.0010165545765463517,0.0011245256173612694
NCT00028431,Novel Adjuvants for Peptide-Based Melanoma Vaccines,0.0010667358109687048,0.0009337459541382568
NCT00017121,Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0010354319828129272,0.0012274610728936319
NCT00006035,Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011653823749232693,0.0011964407705851686
NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",0.001028070806789816,0.0012123551472199162
NCT00006243,Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma,0.0012122590028419138,0.0013196958745200868
NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,0.0012317918389425527,0.0010152103054445949
NCT00006022,Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer,0.0010805244216807828,0.0012620623391814978
NCT00006113,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.001201035011179275,0.0012737165761949286
NCT00006233,"Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",0.0010430171180609738,0.0012396317619590693
NCT00006249,Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma,0.0012064249133794719,0.0011163192727257072
NCT00084214,STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma,0.0010495452011953922,0.0014217259733052814
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,0.0011652808925316227,0.0012211223115055213
NCT00042783,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013875747156188902,0.0015070811116913874
NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,0.001192603620063102,0.0011723034579891195
NCT00087386,Tanespimycin in Treating Patients With Stage III-IV Melanoma,0.0013305016006026663,0.0011001011618854684
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,0.0013958950450768603,0.0012935300004421565
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,0.0011408412741450043,0.0011175243582476166
NCT00083239,Study of Talabostat in Advanced Melanoma,0.0014208975651701526,0.0017036989680137065
NCT00083252,Study of Talabostat and Cisplatin in Advanced Melanoma,0.0011377061833540967,0.001352178488475991
NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013875747156188902,0.0014047894390818384
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,0.00140721058988772,0.001589041367160601
NCT00060125,Tipifarnib in Treating Patients With Metastatic Malignant Melanoma,0.001266406642944171,0.001247597939398341
NCT00016263,Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma,0.001100164951771499,0.0010842448655699677
NCT00010309,"Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",0.0012043136488369228,0.0014222634026542279
NCT00085397,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.001233636878770403
NCT00085189,Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma,0.001292926548003819,0.0014306363479792926
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.0012795719301549595
NCT00085579,Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011442777159797349,0.0010877039887879107
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,0.0010719307553939898,0.0012572109936490204
NCT00014625,E7070 in Treating Patients With Stage IV Melanoma,0.00134567707024725,0.0014300540460734997
NCT00014092,Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery,0.001133702493324469,0.0014102916336811745
NCT00049530,PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma,0.00134567707024725,0.001245448246740586
NCT00025181,Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery,0.0011856107664803394,0.0014032075984491078
NCT00003091,High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma,0.0010245333466557325,0.0011519404334843827
NCT00003266,Methylphenidate in Treating Patients With Melanoma,0.0015300581169501728,0.0009421460873522675
NCT00003646,Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012625216960527848,0.0015149677415924163
NCT00003509,Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,0.0012239477568120668,0.0010871031252385364
NCT00003641,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,0.0010964723047764734,0.0010586270204141818
NCT00003911,S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,0.000730676690432049,0.0009534114360205551
NCT00003346,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012619250060555444,0.001341295215841716
NCT00003308,"Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",0.0009963232280623684,0.0011302175089445876
NCT00003647,Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011898666360838268,0.0012152235510089256
NCT00003556,Vaccine Therapy in Treating Patients With Melanoma,0.0015849858625954353,0.0014271839105772122
NCT00003715,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,0.0011963345850461939,0.001132927906917479
NCT00003789,Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg,0.001059901213039145,0.0009610480804531507
NCT00003897,Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma,0.0011083194636554658,0.0013618260530577078
NCT00003895,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,0.00127082996819914,0.0012272583342200424
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012075189438423982,0.0013588894096735898
NCT00003828,S9804: Vinorelbine in Treating Patients With Stage IV Melanoma,0.001346445681736535,0.0013172530099116117
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013875747156188902,0.0014012748157466626
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,0.0012129197819598547,0.0013341462864255727
NCT00003339,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,0.0012029061089258509,0.0012664981010348465
NCT00062491,Study of Karenitecin (BNP1350) to Treat Malignant Melanoma,0.001258500554899332,0.0019097284099978522
NCT00091689,Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions,0.0007914296566717808,0.0010907525114828758
NCT00057616,Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.,0.0009338046306838496,0.0010238269433927242
NCT00055562,Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma,0.0009294510756319302,0.0010168341049113573
NCT00040352,"Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma",0.0008505122814831263,0.000958409317854296
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,0.001322411624210539,0.001080730215456106
NCT00077532,Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma,0.0010612965623049522,0.0011632756207288599
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.001442170621778284
NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013875747156188902,0.0013870815087578647
NCT00039091,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",0.0009598579479118762,0.0008645904270174624
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,0.000909692478225085,0.0010163750645271993
NCT00039234,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver,0.001087303658331392,0.0010623491068862956
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,0.0010336576554685847,0.0011847112467040458
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,0.0013716762758666666,0.001240427585735042
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,0.0013875747156188902,0.0011848377432020262
NCT00059800,Boron Neutron Capture Therapy in Treating Patients With Melanoma,0.0015329794314708684,0.0013595177488045513
NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,0.0011872917699966843,0.0014004632408024427
NCT00072163,Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma,0.0010318629686434917,0.001078613589588352
NCT00072124,Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma,0.0010995188186986202,0.0011333649574832498
NCT00072345,"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",0.0011552816181203212,0.0013785395066463488
NCT00020358,Vaccine Therapy in Treating Patients With Melanoma,0.0015849858625954353,0.0014206863634648465
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,0.001111788569857409,0.0010344403677378477
NCT00068172,Study of PI-88 in Patients With Advanced Melanoma,0.0015207253704599014,0.0020788584137047543
NCT00068666,Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System,0.0010891972878528393,0.0010591598559263947
NCT00036764,BMS-247550 in Treating Patients With Stage IV Melanoma,0.0013456770702472496,0.0014300540460734997
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,0.0010711960420971265,0.0013831186625697014
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.0010489117023767267,0.0010999492664932145
NCT00002763,High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma,0.0011183692797234067,0.0010526928530664801
NCT00002781,Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma,0.0013324450784554874,0.0013260440234934446
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,0.0010923186994370839,0.001285570820786708
NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,0.001079816349882209,0.0009943122774162087
NCT00002535,Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma,0.0011707245301669379,0.0012289934857904643
NCT00005057,Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma,0.0011703061613961062,0.0012293748518623824
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,0.0012052317672795834,0.0013971330743653024
NCT00005815,Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma,0.0011844676152457153,0.0013681371289923742
NCT00005633,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.0012795719301549595
NCT00005610,Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0011319920842126942,0.0011511208665856542
NCT00005968,Irofulven in Treating Patients With Stage IV Melanoma,0.0013456770702472496,0.0014300540460734997
NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.0012812594926116486
NCT00005971,Flavopiridol in Treating Patients With Metastatic Malignant Melanoma,0.0012656745851808756,0.0013615330280375719
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,0.0011951168225391008,0.001359882802681867
NCT00086866,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery,0.0012106429344163464,0.0012223847473906222
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",0.001693464656063109,0.001551260690540199
NCT00004244,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma,0.001042248203531882,0.0010212090775505273
NCT00004135,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer,0.0010416260398739378,0.0012177468321843846
NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,0.0012066313918883025,0.0014899057806489254
NCT00004250,Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery,0.0010063620098579825,0.0009491037146021486
NCT00004104,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,0.0011184848384458816,0.0011199538796941378
NCT00004184,Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.001263221985703847,0.0012564091932144562
NCT00004153,Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma,0.0010110640074465168,0.0007999919564378567
NCT00004152,PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma,0.0011365063821663541,0.0010337741946503923
NCT00004025,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012075189438423982,0.001508531887056233
NCT00004196,Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis,0.001085076073979441,0.001210201237781511
NCT00080353,Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma,0.0008952384817137215,0.0014704744102260845
NCT00024011,PS-341 in Treating Patients With Metastatic Malignant Melanoma,0.001266401043603081,0.0013618546450567082
NCT00001296,"A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma",0.0010448972592064744,0.0008344992584406413
NCT00001685,"Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",0.0009997450996677237,0.00114131059671049
NCT00001439,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,0.000894439686960266,0.000980269266968389
NCT00001577,Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity,0.0008408197696068161,0.0007265294746841173
NCT00035165,EPO906 Therapy in Patients With Advanced Melanoma,0.00140721058988772,0.0012960439857697406
NCT00007969,Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012613364943483052,0.0013586259062005244
NCT00026520,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,0.0011784778898464234,0.0013139157468634928
NCT00026221,Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011167520306708987,0.000978242287059744
NCT00026143,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011129064457527779,0.0012401982391764975
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.001469376879652042
NCT00098553,Everolimus in Treating Patients With Stage IV Melanoma,0.0013471459179271452,0.0011350261668349345
NCT00089193,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0011842717391288044,0.0011510598797221348
NCT00089219,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",0.0012320556545119359,0.0012746521312527123
NCT00089063,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,0.001151498527900461,0.0011036278442784894
NCT00089206,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0012106429344163464,0.0012640785600549665
NCT00073892,PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma,0.0012864896478213068,0.0014179878735890092
NCT00032045,Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0012065170781847042,0.001263412579165164
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",0.0011534324514237621,0.0012884964092867524
NCT00031733,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,0.0010203916706572405,0.001097339406874746
NCT00095108,Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer,0.0009471555595626028,0.0009811956441487081
NCT00070642,CPG 7909 Injection in Melanoma,0.0014639946636531749,0.0012642565523052858
NCT00070343,Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301,0.0011151554252509376,0.0011568191283794506
NCT01456104,Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma,0.0010047472490231696,0.001118335996034233
NCT01496807,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,0.0008722099953024117,0.001009114744960522
NCT01460875,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,0.0015398860144295895,0.0015117939038514151
NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,0.0009030942919495817,0.0010626938717763095
NCT01409733,TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients,0.0009909999416962353,0.0011082630157452772
NCT01489423,Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim,0.0011635637455156148,0.0012110455919507681
NCT01489059,Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma,0.001116230333138227,0.0010547750549359364
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),0.0009946941936282102,0.0011268366558042794
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,0.001453768898870721,0.001098061408556291
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",0.0010664426650983517,0.001220255618289985
NCT01444560,"miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi",0.0007492663419800073,0.0006588606538387398
NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,0.0008417993344505851,0.0010774611138548312
NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,0.00111531759591984,0.001121333077110374
NCT01432860,A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination,0.0010015934840747862,0.0006432624732470878
NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",0.0011701059988348864,0.0010820038391579755
NCT01453361,Phase II FANG™ in Advanced Melanoma,0.0011882615699658925,0.0009679866227491867
NCT01469455,DNA Repair Inhibitor & Irradiation on Melanoma,0.0008551837055842262,0.0011070563874989406
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,0.0010241751010021346,0.0009068409710197998
NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,0.0011365684388256884,0.0012581619180813818
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,0.0013594136897959286,0.0011292012227842193
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,0.0009407557871849943,0.0009881482749331649
NCT01455103,Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma,0.0011491298675690975,0.0014300798697794675
NCT01295931,Nuclear and Near-Infrared (NIR) Imaging in Melanoma,0.001470301081975591,0.0006612290900182773
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",0.0009354730914292868,0.0011451897800092408
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,0.0014139764207564353,0.0013133993858699849
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,0.0015321254055288946,0.0015054953123920562
NCT01213732,Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma,0.0009226404481269681,0.0008935180181221872
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,0.0011027747780720744,0.001062712660394985
NCT01259934,Nordic Adjuvant IFN Melanoma Trial,0.002786251250086908,0.0010701850739902763
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma",0.0010962040090208073,0.001222993520554809
NCT01227551,A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma,0.0013477423175207595,0.0012646549661520185
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,0.0011001754287671152,0.0010385866832404074
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,0.0011484842832631657,0.0011275641430158417
NCT01216787,"RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",0.0011734242178892515,0.0012953758286117817
NCT01256359,Docetaxel With or Without AZD6244 in Melanoma,0.0014582861699868324,0.0012445535145998701
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,0.0009030541371034992,0.0010022409669955261
NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,0.001081833263248618,0.0013732949385658957
NCT01280565,A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit,0.0013402079496886226,0.0010544917599148386
NCT01281722,Role of SLURP-1 in Melanoma and Melanoma Stem Cells,0.0008563937298758259,0.0008210273407007113
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,0.000988152514937951,0.001054222250888122
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,0.0008916336721545493,0.001003364573921071
NCT01205815,Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment,0.00129229777214791,0.0011025798186482408
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,0.0011353118701921073,0.0013401002389294204
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,0.001130860976441792,0.0013200814084895224
NCT01209676,IMCgp100 in Advanced Unresectable Melanoma,0.0010074503222461217,0.0007878228522764696
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,0.0007209659381067718,0.0008650073685670026
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,0.001195820338370749,0.0012004211146373278
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,0.0012227287581050375,0.0009866373378205338
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0010937185175476294,0.001276851711652669
NCT02941744,A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases,0.0007450126501562928,0.0008382241627155507
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,0.0008463813166262024,0.0009526665435459047
NCT02990611,Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma,0.0011835677435170953,0.001144687294461259
NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,0.0009462162121013613,0.0008864097953466983
NCT02907827,Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.,0.000997999189343018,0.0006789285822628102
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,0.0010723534055435036,0.001052805824561213
NCT02975700,A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma,0.0012944536416108997,0.0013372339150684847
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,0.0008277633073441487,0.0012785216391067247
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,0.0009499127392138223,0.001109317122709015
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,0.0010421991632975304,0.0009966952999159384
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,0.0012205579752600502,0.0013609813679954866
NCT02909348,Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab,0.0011392701953157423,0.001039342309491008
NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,0.0009187018896853,0.0010687136298193605
NCT02994498,DCB-BO1301 for Advanced Melanoma,0.0016981567847504184,0.0012951233374946325
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,0.001108007485800096,0.0012602852907839979
NCT02905266,A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,0.0009012290514724282,0.0010179495102007538
NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",0.0010458005762882061,0.0009042729299726797
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0013554904432607076,0.001354414423551453
NCT02962947,MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients,0.0012253722855662104,0.0011635893061578784
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,0.0010141207708490706,0.0009578485018210631
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,0.0015587429553357943,0.0011240007098273748
NCT02915666,A Clinical Trial of Patients With Melanoma,0.0015399070196748068,0.0011224769170729816
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,0.0010219855567994715,0.0011161976131599878
NCT02910557,Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection,0.0012133712641480372,0.0011029053486596256
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",0.0009578679531412333,0.0009878820828429472
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,0.0009832151308960995,0.0009399328954073898
NCT02507947,SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access,0.0010983641876157434,0.0010099600217515544
NCT02507076,Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma,0.0010253634552275833,0.0011450597433873434
NCT02519322,Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,0.0011371417963311182,0.0011657473767261498
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Hodgkin Lymphoma or Other Solid Tumors",0.0008237362579532734,0.0007941644578099545
NCT02508909,Videoscopic Ilioinguinal Lymphadenectomy for Melanoma,0.0014552543457432231,0.0006739319061834965
NCT02545075,A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine,0.0008579135783783785,0.0010253088417713628
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),0.001102426084960213,0.001078258441122251
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,0.0008133280810074851,0.0011410230177798127
NCT02511119,Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma,0.000699766132622765,0.0007519949424342041
NCT02574377,myDC/pDC in Stage III Melanoma Patients,0.0016798269232940661,0.0012077130144388327
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,0.001016627538949536,0.001259471183151303
NCT02509598,"A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping",0.0011001559880687098,0.0009410884444958329
NCT02565992,Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma,0.001160447114369571,0.0010171156386297626
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,0.0011508875324772923,0.0013342297991886356
NCT02506153,"High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",0.0011342291667625014,0.0011261242535340898
NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",0.0011489186823987337,0.0011095470619235186
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,0.0010814744754555933,0.001096544317631961
NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients,0.0015637059198088227,0.0019135170763461475
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",0.0009001952827505952,0.000818171763222328
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,0.0008724300571081895,0.0008234342895020941
NCT02587650,Trial of TKF Inhibition in Unresectable Stage III/IV BRAF/NRAS WT Melanoma,0.0009970765408016508,0.0010856332907131826
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,0.0007278940299405039,0.001044607501531864
NCT00626405,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,0.001102037298240684,0.0011311389933179807
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,0.0011325492045195279,0.001402724327467161
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,0.001693464656063109,0.0012581705889176157
NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.001179065702617808,0.0013145323395861166
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",0.0009720455539335961,0.0006738388714444296
NCT00667953,Study of Temzolomide and Gleevec in Advanced Melanoma,0.0011347506173300062,0.0011816764787610141
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,0.0008227401077852407,0.0014525347625993085
NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,0.0009186577479745611,0.0008428599298689471
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",0.0009581091968934334,0.0009586776136726207
NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,0.0008819426127284074,0.0011889898985846272
NCT00610857,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,0.0011134074478241836,0.0009671506029060724
NCT00625768,Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma,0.0011655430361672211,0.0011798020738419876
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,0.0008765686959783021,0.0010909303632311658
NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,0.0007636634918676755,0.0013008905437591953
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,0.0008098195408300821,0.0010400266896299375
NCT00672321,"Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma",0.0010006864775919063,0.0007290668955234704
NCT00669019,Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011781637356921395,0.0012156829628828364
NCT00658892,Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0013485916472626956,0.0009203398390521297
NCT00658437,CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy,0.0010265947325163052,0.001238107815061324
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,0.0010941374247145136,0.0012040806780718634
NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,0.0009976958497546783,0.0011934163006840518
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",0.0014598670721664298,0.0011498710486836567
NCT00675727,Safety Study of CADI-05 in Patients With Advanced Stage Melanoma,0.0013474617601464494,0.001254807392462278
NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,0.0010198331102207656,0.0010713554079555192
NCT00601861,Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer,0.0007583987597697051,0.0007371514655492706
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,0.0010619719602771693,0.0010486477298847347
NCT00602576,Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma,0.0010829686559327492,0.001062410989576761
NCT00615095,Differential Risks for Melanoma: p16 and DNA Repair,0.0014552889022528903,0.000784249622470986
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,0.0014553297306503336,0.0009498739891667004
NCT00698100,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",0.0011041856006016749,0.0010219597493338732
NCT00671554,Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma,0.0010318195974292589,0.001093590533262116
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.000707153388498272,0.000631565058021128
NCT00398073,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0012238164513765984,0.0012026577944473866
NCT00349206,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010685661139745234,0.0010620761337589348
NCT00306553,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001117277682560174,0.0012337038120688675
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,0.0010968376080635897,0.001134601930776284
NCT00306514,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001117277682560174,0.0012155327576980407
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,0.0010258806135737756,0.0010512111549994603
NCT00383292,A Study of LY573636 in Treating Patients With Malignant Melanoma,0.0017627199232994701,0.0013233573724556465
NCT00383851,Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma,0.000979356310348814,0.0011449680244474993
NCT00328861,Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer,0.000861727277824535,0.0013966074546440986
NCT00346008,Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members,0.001532015247659573,0.0008582001696419975
NCT00368615,Characterization of the Melanoma-Specific Immune Response,0.00085584453247275,0.0010286491581592578
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,0.0008341087997531892,0.000540135121514366
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,0.0014597955497310912,0.0008833878856973605
NCT00348088,Melanoma Biomarker Study,0.0012763705125327868,0.0009297428481755235
NCT00304200,Temodar and Sutent as Therapy for Melanoma,0.0008979568618888282,0.0009838802162785124
NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.001173864819676621,0.0010388280745282062
NCT00394134,Targeted Intervention for Melanoma Prevention,0.001027905494348073,0.0007061143027643014
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,0.001078367777759201,0.0008992728083625867
NCT00356460,Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma,0.0012605143104683172,0.000921154904588029
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,0.0013479626693052153,0.0012785751548834872
NCT00387751,Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011668380807444844,0.0010623606014453098
NCT00391300,Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions,0.0009651113139038422,0.0007499589770587802
NCT00341991,Molecular Epidemiology of Cutaneous Malignant Melanoma,0.0010283698246578413,0.0007470587280502542
NCT00357461,Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma,0.001256853765516879,0.001225179900874555
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,0.0011809235013764614,0.0011561942790772883
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,0.001040860948649294,0.0014153186400368892
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012962648566564939,0.001244862010572714
NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,0.0011704755897338785,0.001330940512632434
NCT00327600,Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma,0.0009744174883466852,0.0010728457306490998
NCT00339222,Family Study of Melanoma in Italy,0.001453768898870721,0.0007399848690879706
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,0.0008485092221521262,0.0009854688943877466
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,0.0010278502686851077,0.0010826429497743943
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,0.001032810660651408,0.0010426129955904793
NCT00791271,Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion,0.0008432337641888554,0.0009069292076765754
NCT00723710,Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600),0.0011212523519422777,0.001003824199233882
NCT00794235,Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,0.0008556408955950143,0.0009634170426192691
NCT00790010,Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma,0.0011600689952698676,0.001137395209897984
NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,0.0009330115575331824,0.0009773761365893942
NCT00749684,Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083),0.0009038904966143021,0.0008419821908055397
NCT00716495,"Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma",0.000997355557303063,0.0010318040065340056
NCT00726739,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0012099432733846734,0.0011897578378253118
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,0.0013988824656002926,0.0015961245203861092
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",0.001114221340418988,0.0010476456649629868
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,0.001016016019853588,0.0011211247781738422
NCT00796445,"A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",0.0011458976209075262,0.0011337333792101674
NCT00707161,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,0.0008511602632213137,0.00112473011062432
NCT00788775,"Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",0.0009929763635522114,0.0009466600792301926
NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,0.0011031334799599724,0.001062972694263369
NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients,0.0012467117309016586,0.0014251123827732817
NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,0.0011856721159011069,0.0011922542790609352
NCT00776945,Feasibility and Functionality of fPAM Imaging in Melanoma,0.001037394707743883,0.0006569745920513923
NCT00743496,"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",0.0007431343279666135,0.0009510517803787782
NCT00705640,Vaccine Therapy in Treating Patients With Advanced Melanoma,0.0013837066687957592,0.0012736937467762032
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011285534000958447,0.001192288045259333
NCT00445783,Study of Families With Melanoma,0.0018006310967869853,0.001110874846977247
NCT00466687,Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma,0.0011767237004383436,0.0009858116350218756
NCT00477906,M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma,0.0010539178445968535,0.001361661391562981
NCT00450255,VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011781637356921395,0.0010972812334958905
NCT00450593,Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma,0.0012177492610887597,0.0011101943574568726
NCT00457418,High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2),0.0011453540094527263,0.001150745424326681
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",0.0010534964878741871,0.001051389108784275
NCT00412828,A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010455420256665839,0.0010020196141408552
NCT00409383,Abraxane and Temodar Plus Genasense in Advanced Melanoma,0.000847070531272687,0.0009980079877035166
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,0.0010099568814657754,0.0014021600923565154
NCT00472459,PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer,0.0007419924367639066,0.0009545937253275646
NCT00463892,High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes,0.0007155005948426182,0.0009460019782663103
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,0.0012199499203486832,0.0009340524482713226
NCT00436605,Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma,0.001179003955976445,0.0011576550794752559
NCT00462280,Lovastatin in Treating Patients At High Risk of Melanoma,0.0012229670179034376,0.0014081126480850852
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",0.0011794826454578026,0.0010758683467004503
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,0.0010866155422612016,0.0011450912638803336
NCT00447356,High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma,0.001091359276180036,0.0009576259738993347
NCT00406900,Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma,0.0007929455316000002,0.0009482657825654043
NCT00432107,A Study to Assess APO866 for the Treatment of Advanced Melanoma,0.0012001368680674912,0.0011155089783373966
NCT00432471,Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers,0.0010330935484847105,0.0008028080809901144
NCT00416988,Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants,0.0007460330329812341,0.0005754769861350445
NCT00404235,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.001152278185280039,0.0011218107293952684
NCT00470015,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",0.0011489076959580544,0.0011728588734463868
NCT00470379,"Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",0.0011820075790643367,0.00118114085734018
NCT00470470,Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011785832179776962,0.0012159761991991874
NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",0.0010956431961532066,0.0011858309842503454
NCT00438009,A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients,0.0013966342306699223,0.0009890886020451353
NCT00471133,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,0.0008397254132211959,0.0008625699208310319
NCT00471887,"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",0.001197125221333941,0.0010450378988445788
NCT00471471,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012106429344163464,0.0011554994136039976
NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",0.0008223775137256663,0.0009091263286480524
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",0.001031401287609413,0.0007883869310284891
NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,0.0011057541600376327,0.0011172872277944986
NCT00482105,Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells,0.0006997424404502002,0.0006371361070168529
NCT00495066,Compassionate Use Trial for Unresectable Melanoma With Ipilimumab,0.0009463382081396922,0.0009967044679306738
NCT01886235,Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery,0.0010436248307405186,0.0012236069452591046
NCT01840527,Utility of Novel BRAF Test for Melanoma,0.0014611182470397174,0.0009208367189678135
NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,0.0012604867940840389,0.0009714480025708715
NCT01888081,A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma,0.000855432088947894,0.0010419219049164134
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,0.0010367287032979873,0.001040554864748007
NCT01864538,A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma,0.0011491298675690975,0.0011843428937799848
NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",0.0009471222938189376,0.0009535180268199154
NCT01826864,Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma,0.0010249297301271525,0.0013161605356506302
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,0.0010243515560704908,0.0011596871571769901
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",0.0011601106756495723,0.001364951495053275
NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,0.0011899116827122109,0.001593365822252703
NCT01867619,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.0010856670686025679,0.0011075867297094847
NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,0.0010899368625444156,0.0012067673050891717
NCT01878396,Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors,0.0011216986366022683,0.0013775038352623883
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,0.0010004695111617405,0.0014000806245220096
NCT01859845,Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma,0.0006820207528875561,0.0006919378049654162
NCT01866319,Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006),0.0009774585515858836,0.0009998453436718521
NCT01844505,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),0.0009704960361676553,0.0010968291451616532
NCT01898403,Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma,0.0010683733397412111,0.0010677521671254688
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,0.001323783159161514,0.0010277017162131491
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,0.0010610784872913572,0.0012133046803510634
NCT01851408,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010685661139745234,0.0010620761337589348
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011384988685780532,0.0011796146150766507
NCT01920516,Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment,0.0008062395697033416,0.0010752456579543575
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,0.0010747235667035488,0.0011486246787704997
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",0.0010666443693500012,0.0011534869890928096
NCT01989572,Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma,0.0010944671935643612,0.0012513459639678854
NCT01989559,Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery,0.001006143291696187,0.001150682261690212
NCT01996202,A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma,0.000903378238276342,0.0009093264433538338
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,0.0013722598711513926,0.002130592781873668
NCT01959633,Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,0.001216951244318609,0.0012845335654571102
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,0.001094591229141266,0.001072693033716565
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,0.0009314878431925149,0.0013397270441359288
NCT01944709,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma,0.0012817737986346488,0.001239612452330778
NCT01986712,A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma,0.0011300439519561908,0.0011091468470351363
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",0.0011003097187740137,0.0012563059575140176
NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,0.0007627172327340206,0.0010693016313079826
NCT01973608,MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma,0.0011882615699658928,0.0007525607566525464
NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,0.0011899022724175315,0.0014361067882133697
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,0.0014909630754963966,0.0011042561511665156
NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,0.0011887628223477486,0.0013570812802840013
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,0.0012644401697316128,0.0010198166559431646
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,0.0012219355604843685,0.0011485781323541011
NCT01904123,A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma,0.0012350664206821752,0.0011094719900481582
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,0.0009281994847847529,0.0011819459071644375
NCT01988831,Efficacy of Propranolol Treatment to Prevent Melanoma Progression,0.000795080929101083,0.0009458420340414326
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",0.0007389090296243927,0.0008580450785834078
NCT01984255,"A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",0.0010829006417723633,0.0009709230618702298
NCT02694965,Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma,0.0008617763235569692,0.0009066788700437333
NCT02602756,Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas,0.0010122928464176442,0.0008414532998545341
NCT02605473,Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion,0.0008432337641888554,0.0009502687049007124
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,0.0009387451607391551,0.0009488316160186462
NCT02696356,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,0.0012742757981968138,0.0011862325044757972
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,0.0010116880791028666,0.0007813583346747038
NCT02671513,A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients,0.0013224057479431183,0.001758723924901612
NCT02613325,fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth,0.0008359211940477874,0.0009210248546338073
NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,0.0011491303148873514,0.0009946867047161533
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,0.0007408326914798321,0.000978535221689554
NCT02600169,Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab,0.0010277942378948705,0.00112095715165577
NCT02600143,Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.,0.0010078670088769675,0.0008387111953411951
NCT02668887,Employment and Quality of Life in Patients With Malignant Melanoma,0.001532994891094447,0.0010504898147396613
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,0.0009130264179968793,0.0008442235255253567
NCT02673970,Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma,0.0011102421516506443,0.0011641467061504673
NCT02662725,Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases,0.001133545357911978,0.000912899729672708
